PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Oncotarget | WNT-pathway medulloblastoma: What constitutes low-risk and how low can one go?

Oncotarget | WNT-pathway medulloblastoma: What constitutes low-risk and how low can one go?
2023-02-27
(Press-News.org) “The definition of low-risk WNT-pathway medulloblastoma may need to be refined in light of recent clinical data and newer biological information.” 

BUFFALO, NY- February 27, 2023 – A new research perspective was published in Oncotarget's Volume 14 on February 7, 2023, entitled, “WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?”

Novel biological insights have established that medulloblastoma is a heterogenous disease comprising four broad molecular subgroups - WNT, SHH, Group 3, and Group 4 respectively, resulting in the incorporation of molecular/genetic information in 5th edition of WHO classification and contemporary risk-stratification. Concerns regarding therapy-related late toxicity in long-term survivors have led to systematic attempts at treatment de-intensification in good-risk medulloblastoma. 

Given the excellent survival (>90%) of WNT-pathway medulloblastoma, prospective clinical trials have focused on optimization of therapy to balance survival versus quality of survival. The currently accepted definition of low-risk WNT-pathway medulloblastoma includes children <16 years of age with residual tumour <1.5 cm2 and no evidence of metastases. This systematically excludes adolescents and young adults who have been perceived to have worse outcomes. 

In a previous study, researchers Shakthivel Mani, Abhishek Chatterjee, Archya Dasgupta, Neelam Shirsat, Sridhar Epari, Girish Chinnaswamy, and Tejpal Gupta from Homi Bhabha National Institute (HBNI) in Mumbai, India, reported long-term survival of an adolescent and young adult cohort that was largely comparable to childhood medulloblastoma. In their current research perspective, the researchers now report on molecularly characterized WNT-subgroup patients treated between 2004–2020 with risk-stratified multi-modality therapy to identify differences between childhood (<15 years) versus adolescent and young adults (>15 years). 

Despite modest differences in disease status at presentation and treatment modality, there were no significant differences in patterns of failure or survival between childhood versus adolescent and young adult WNT-pathway medulloblastoma. Two de-intensification trials in low-risk WNT-pathway medulloblastoma – first testing omission of upfront craniospinal irradiation and second a primary chemotherapy approach after surgery – had to be terminated prematurely due to unacceptably high relapse rates suggesting that craniospinal irradiation remains an integral component of treatment. The presence of TP53 mutations and OTX2 gains have recently been reported as independent negative prognostic factors in a multi-institutional cohort of WNT-pathway medulloblastoma, raising questions on eligibility of such patients for de-escalation trials. 

“Concerns regarding therapy-related late toxicity have prompted systematic attempts at treatment de-intensification in good-risk MB over the last four decades. However, results of prior studies should be used to inform and guide controlled de-intensification of therapy even in low-risk and favourable biology disease. The definition of low-risk WNT-MB may need to be further refined in light of recent clinical data and newer biological information.”

 

DOI: https://doi.org/10.18632/oncotarget.28360 

Correspondence to: Tejpal Gupta

Email: tejpalgupta@rediffmail.com 

Keywords: de-intensification, medulloblastoma, molecular, survival, toxicity

 

About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:

Twitter  Facebook  YouTube  Instagram  LinkedIn  Pinterest  LabTube Soundcloud

For media inquiries, please contact: media@impactjournals.com.

 

Oncotarget Journal Office

6666 East Quaker Str., Suite 1A

Orchard Park, NY 14127

Phone: 1-800-922-0957 (option 2)

###

END


[Attachments] See images for this press release:
Oncotarget | WNT-pathway medulloblastoma: What constitutes low-risk and how low can one go? Oncotarget | WNT-pathway medulloblastoma: What constitutes low-risk and how low can one go? 2 Oncotarget | WNT-pathway medulloblastoma: What constitutes low-risk and how low can one go? 3

ELSE PRESS RELEASES FROM THIS DATE:

Rutgers researchers use artificial intelligence to predict cardiovascular disease

2023-02-27
Researchers may be able to predict cardiovascular disease – such as arterial fibrillation and heart failure – in patients by using artificial intelligence (AI) to examine the genes in their DNA, according to a new Rutgers study.   “With the successful execution of our model, we predicted the association of highly significant cardiovascular disease genes tied to demographic variables like race, gender and age.” said Zeeshan Ahmed, a core faculty member at the Rutgers Institute for Health, Health Care Policy and Aging ...

To promote exercise, planners must look beyond cities

2023-02-27
ITHACA, N.Y. – To encourage more active lifestyles, public health agencies recommend mixed-use neighborhoods and “complete” streets that are friendlier to walkers and bikers, but new Cornell University research finds that while those strategies increase physical activity, an urban bias limits their applicability in many parts of the country. Planners in suburban and rural communities should focus more on promoting recreational programs, expanding transportation options and creating safer environments to help an aging population get more exercise, according to the researchers’ analysis of more than 1,300 U.S. counties and cities. “These ...

Shrinking age distribution of spawning salmon raises climate resilience concerns

Shrinking age distribution of spawning salmon raises climate resilience concerns
2023-02-27
By returning to spawn in the Sacramento River at different ages, Chinook salmon lessen the potential impact of a bad year and increase the stability of their population in the face of climate variability, according to a new study by scientists at UC Santa Cruz and NOAA Fisheries. Unfortunately, spawning Chinook salmon are increasingly younger and concentrated within fewer age groups, with the oldest age classes of spawners rarely seen in recent years. The new study, published February 27 in the Canadian Journal of Fisheries and Aquatic Sciences, suggests changes in hatchery practices and fishery management ...

Ipek receives funding to write book on everyday life of activism in Lebanon

2023-02-27
Yasemin Ipek, Assistant Professor, Global Affairs Program, received funding to write a book on diverse meanings and implications of being an activist in Lebanon. The book, titled: "Crisiswork: Activism, Class-Making, and Bounded Futures in Lebanon," will be a study of the emergent forms of activism and political subjectivity in contemporary Lebanon in relation to lived experiences of crisis.  Ipek aims to answer the question: "How has the recent mobilization of civil society activism shaped politics and everyday life in Lebanon?"  She intends to answer that question by ethnographically studying activism as a contentious ...

Lum and Koper receive funding for application of evidence-based policing to investigations in Seattle police department

2023-02-27
Cynthia Lum, Professor and Director, Evidence-Based Crime Policy (CEBCP), Criminology, Law and Society, and Christopher Koper, Associate Professor, Criminology, Law and Society, received funding for: "Application of Evidence-Based Policing to Investigations in the Seattle Police Department."  The purpose of this contract is to provide the Seattle Police Department with an evidence-based assessment of its investigations practices and to make recommendations on improving the alignment of the agency with evidence-based approaches in this area.  Lum and Koper received $121,363 from ...

Researchers reveal conjugated dual size effect of core-shell bimetallic nanocatalysts

Researchers reveal conjugated dual size effect of core-shell bimetallic nanocatalysts
2023-02-27
Recently, a team led by Prof. LU Junling collaborating with Prof. LI Weixue’s and Prof. WEI Shiqiang’s team, revealed the conjugated dual size effect of core-shell bimetallic nanocatalysts for the first time, with the activity of the catalysts increases with the core size in the benzyl alcohol oxidation reaction. Their work was published in Nature Communications. Bimetallic catalysts are widely used in different chemical synthesis for their bimetallic synergy varying with compositions and structures. Compared to alloy catalysts, the peculiar lattice ...

Babies born preterm decreased slightly and stillborn rates unchanged during first wave of COVID-19 lockdowns

Babies born preterm decreased slightly and stillborn rates unchanged during first wave of COVID-19 lockdowns
2023-02-27
Babies born preterm decreased and stillborn rates remained unchanged during the first four months of COVID-19 lockdowns, according to a largescale international study. The research of 52 million births from 26 countries, published in Nature Human Behavior, reported a 3-4 per cent reduction overall in preterm births, averting almost 50,000 preterm pregnancies during the first month of lockdown alone. But the decrease in preterm births was limited to only high-income countries including Australia. The International Perinatal Outcomes in the Pandemic (iPOP) Study, ...

Plugging immune cell leakage from tumors could improve skin cancer treatment

2023-02-27
The number of specialized immune cells available for fighting skin cancer doubled when a new treatment blocked their escape from melanoma tumors, experiments in mice and human cells show.  Researchers at NYU Langone Health and its Perlmutter Cancer Center who led the study found that combining a chemical blocker of immune cell exit with another drug type, an immunotherapy, stopped melanoma tumor enlargement in more than half of mice tested. Immunotherapy alone had previously failed to prevent the cancers’ growth. Recent advances in immunotherapies, medications designed to help the body’s immune defense system ...

Corralling ions improves viability of next generation solar cells

2023-02-27
Researchers have discovered that channeling ions into defined pathways in perovskite materials improves the stability and operational performance of perovskite solar cells. The finding paves the way for a new generation of lighter, more flexible, and more efficient solar cell technologies suitable for practical use. Perovskite materials, which are defined by their crystalline structure, are better at absorbing light than silicon is. That means that perovskite solar cells can be thinner and lighter than silicon solar cells without sacrificing the cell’s ...

Cleveland Clinic study finds common artificial sweetener linked to higher rates of heart attack and stroke

Cleveland Clinic study finds common artificial sweetener linked to higher rates of heart attack and stroke
2023-02-27
Monday, February 27, 2023, Cleveland: New Cleveland Clinic research showed that erythritol, a popular artificial sweetener, is associated with an increased risk of heart attack and stroke. Findings were published today in Nature Medicine. Researchers studied over 4,000 people in the U.S. and Europe and found those with higher blood erythritol levels were at elevated risk of experiencing a major adverse cardiac event such as heart attack, stroke or death. They also examined the effects of adding erythritol to either whole blood or isolated platelets, which are cell fragments that clump together to stop bleeding and contribute to blood clots. Results revealed that ...

LAST 30 PRESS RELEASES:

Lower doses of immunotherapy for skin cancer give better results

Why didn’t the senior citizen cross the road? Slower crossings may help people with reduced mobility

ASH 2025: Study suggests that a virtual program focusing on diet and exercise can help reduce side effects of lymphoma treatment

A sound defense: Noisy pupae puff away potential predators

Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukemia patients eligible for intensive chemotherapy

Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes

New findings support a chemo-free approach for treating Ph+ ALL

Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

University of Cincinnati experts present research at annual hematology event

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer

ASH 2025: New study shows that patients can safely receive stem cell transplants from mismatched, unrelated donors

Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient

Continuous and fixed-duration treatments result in similar outcomes for CLL

Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia

Chemotherapy and radiation are comparable as pre-transplant conditioning for patients with b-acute lymphoblastic leukemia who have no measurable residual disease

Roughly one-third of families with children being treated for leukemia struggle to pay living expenses

Quality improvement project results in increased screening and treatment for iron deficiency in pregnancy

IV iron improves survival, increases hemoglobin in hospitalized patients with iron-deficiency anemia and an acute infection

Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients

Emergency departments fall short on delivering timely treatment for sickle cell pain

Study shows no clear evidence of harm from hydroxyurea use during pregnancy

Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease

Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia

Early results suggest exa-cel gene therapy works well in children

NTIDE: Disability employment holds steady after data hiatus

Social lives of viruses affect antiviral resistance

Dose of psilocybin, dash of rabies point to treatment for depression

Helping health care providers navigate social, political, and legal barriers to patient care

Barrow Neurological Institute, University of Calgary study urges “major change” to migraine treatment in Emergency Departments

[Press-News.org] Oncotarget | WNT-pathway medulloblastoma: What constitutes low-risk and how low can one go?